PCVX
Vaxcyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$61.25
+0.13%Sep 3, 2026, 20:43 UTC
Vaxcyte, Inc. appointed Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer, effective September 3, 2026.
Aug 23, 2026, 08:10 UTC
Deutsche Bank AG acquired a new minority stake in Vaxcyte, Inc., purchasing 258,338 shares valued at approximately $15.02 million, representing 0.18% ownership, as disclosed in an SEC filing.
Source:Aug 16, 2026, 19:45 UTC
Baupost Group eliminated its entire 800,000-share stake in Vaxcyte during the June quarter, as disclosed in its 13F filing on August 13, 2026.
Source:Aug 5, 2026, 00:00 UTC
Vaxcyte, Inc. reported a net loss of $284.3 million for Q2 2026, with diluted EPS of -$1.97.
Jun 23, 2026, 00:00 UTC
Moncef Slaoui was appointed as a Class II director on the Board of Directors of Vaxcyte, Inc., effective June 17, 2026.
Jun 23, 2026, 00:00 UTC
Jacks Lee retired from the Board of Directors of Vaxcyte, Inc., effective June 17, 2026.
Jun 2, 2026, 20:05 UTC
Vaxcyte dosed the first participant in a Phase 1 study of its VAX-A1 vaccine candidate for Group A Streptococcus prevention.
Source: